Benzinga · Oct 16, 2026
Wells Fargo Maintains Overweight on QXO, Lowers Price Target to $15
Wells Fargo analyst Sam Reid maintains QXO (NYSE:QXO) with a Overweight and lowers the price target from $16 to $15.
QX
NASDAQ · QXO
QXO Inc
Technology · Software - Application
$10.51
Down-$0.51 (-4.63%)
Updated Oct 24, 2026, 2:19 AM
SID Score
4.3/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 14.92B
- P/E ratio
- -0.89
- Dividend yield
- 0.00%
- 52-week range
- $10.04 – $27.61
- Volume
- 18.37M
- Avg. volume
- 7.84M
Price performance · QXO
QXO price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 23, 2026
QXO closed at $10.51 after 21 trading sessions, down 15.45% for the selected period.
- Last close
- $10.51
- Period change
- -15.45%
- Period low
- $10.14
- Period high
- $12.43
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 23, 2026 | $10.88 | $11.02 | $10.44 | $10.51 | 18.37M |
| Oct 22, 2026 | $10.17 | $11.11 | $10.17 | $11.02 | 25.1M |
| Oct 21, 2026 | $10.56 | $10.62 | $10.145 | $10.31 | 18.89M |
| Oct 20, 2026 | $10.05 | $10.7177 | $10.04 | $10.46 | 18.85M |
| Oct 19, 2026 | $10.95 | $11.00 | $10.035 | $10.14 | 21.7M |
| Oct 16, 2026 | $11.22 | $11.305 | $10.77 | $10.86 | 20.71M |
| Oct 15, 2026 | $10.62 | $11.20 | $10.49 | $11.18 | 28.59M |
| Oct 14, 2026 | $10.60 | $10.6899 | $10.17 | $10.33 | 34.05M |
| Oct 13, 2026 | $10.635 | $11.19 | $10.635 | $11.02 | 21.65M |
| Oct 12, 2026 | $10.695 | $10.77 | $10.39 | $10.64 | 17.45M |
| Oct 9, 2026 | $11.16 | $11.203 | $10.75 | $10.81 | 20.55M |
| Oct 8, 2026 | $11.03 | $11.17 | $10.77 | $11.12 | 36.06M |
| Oct 7, 2026 | $11.70 | $11.73 | $10.77 | $11.31 | 46.47M |
| Oct 6, 2026 | $12.15 | $12.59 | $12.07 | $12.11 | 23.05M |
| Oct 5, 2026 | $11.99 | $12.15 | $11.77 | $11.88 | 15.61M |
| Oct 2, 2026 | $12.45 | $12.4899 | $11.952 | $12.06 | 16.8M |
| Oct 1, 2026 | $11.60 | $12.18 | $11.37 | $12.05 | 21.87M |
| Sep 30, 2026 | $11.84 | $11.98 | $11.64 | $11.69 | 25.4M |
| Sep 29, 2026 | $12.17 | $12.235 | $11.55 | $11.62 | 22.36M |
| Sep 28, 2026 | $12.12 | $12.21 | $11.82 | $12.12 | 23.19M |
| Sep 25, 2026 | $12.24 | $12.50 | $12.02 | $12.43 | 16.54M |
Latest QXO news
The latest Smart Investors Daily articles mentioning QXO.
Stock researchCompany · Overview
Company
Market Activity
Research & News
QXO research
Overview
Company profile and research snapshot.
Company profile
QXO Inc is the publicly traded distributor of roofing, waterproofing and complementary building products in the United States. The company aims to become the tech-enabled leader in the approximately $800 billion building products distribution industry and generate outsized value for shareholders. It is targeting nearly $50 billion in annual revenues within the next decade through accretive acquisitions and organic growth.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $30.17
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 16, 2026 | Wells Fargo | Overweight | — |
| Oct 13, 2026 | Wells Fargo | Overweight | — |
| Oct 8, 2026 | Truist Securities | Buy | — |
| Oct 7, 2026 | RBC Capital | Outperform | — |
| Aug 25, 2026 | DA Davidson | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 15, 2026
QXO (QXO) Has an $18 Billion Revenue Base. Can Earnings Grow in a Housing Slump?
Why QXO’s Expansion Faces a Housing Test QXO, Inc. (NYSE:QXO) has built a substantially larger building products business just as the housing market is losing momentum. Its July 1, 2026, purchase of TopBuild brought the combined historical revenue base above $18 billion, but that scale alone does not establish whether the acquisition strategy can deliver […]
Benzinga · Oct 13, 2026
Wells Fargo Maintains Overweight on QXO, Lowers Price Target to $16
Wells Fargo analyst Sam Reid maintains QXO (NYSE:QXO) with a Overweight and lowers the price target from $18 to $16.
Yahoo · Oct 12, 2026
QXO (QXO): 61% Drawdown Creates an Asymmetric 37% Annualized Return Opportunity
Patient Capital Management, based in Baltimore, released its third-quarter 2026 investor letter for the “Patient Opportunity Equity Strategy”. The letter can be downloaded here. The Opportunity Equity Strategy outperformed the S&P 500 in the latest quarter, gaining 4.32% compared to 2.30%, and is up 14.93% year-to-date versus the index’s 12.75%. The market shows resilience, despite rate […]
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
